[Form 4] Vita Coco Company, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vita Coco insider Form 4: Martin Roper stock sales and option holdings. The filing reports that Martin Roper, CEO and director, sold four blocks of common stock on 09/18/2025 pursuant to a Rule 10b5-1 trading plan, disposing of 5,000 shares in his name and 5,000 shares each tied to three family trusts for a total reported disposals of 20,000 shares at weighted average prices around $40.00–$40.11 per share. The filing also discloses substantial currently exercisable and non-exercisable non-qualified stock options totaling 1,098,460 underlying shares across multiple grants with exercise prices ranging from $10.178 to $32.78.

Positive

• Sales executed under a Rule 10b5-1 trading plan, indicating pre-established, documented trading instructions
• Substantial option holdings disclosed totaling 1,098,460 underlying shares across multiple grants, showing retained insider equity upside
• Clear ownership disclosure separating direct holdings and indirect holdings via family trusts and spouse

Negative

• Reported disposals of 20,000 common shares on 09/18/2025 at weighted average prices around $40.00–$40.11
• Potential future dilution from large option pools with exercise prices as low as $10.178

Insights

Financial Analyst

TL;DR: Insider sold 20,000 shares under a 10b5-1 plan while retaining over one million potential shares through stock options.

The sale of 20,000 common shares by Martin Roper was executed pursuant to a Rule 10b5-1 plan, which documents pre-established trading and typically mitigates concerns about opportunistic timing. Reported weighted average sale prices ranged from approximately $40.00 to $40.11. The filing also shows material option holdings: multiple grants aggregate to 1,098,460 underlying shares, including large fully vested, exercisable options at $10.178 and multi-year grants with higher strike prices. For investors, the key facts are the existence of the trading plan and the sizable option positions that preserve potential future insider equity dilution and incentive alignment.

Corporate Governance Expert

TL;DR: Disclosure follows governance best practices: 10b5-1 plan sales and clear identification of direct and trust ownership.

The Form 4 identifies Martin Roper as both CEO and a director and discloses sales executed under a documented 10b5-1 trading plan, enhancing disclosure transparency. Ownership is reported as a mix of direct and indirect (family trusts and spouse), and the filing specifies vesting schedules for option grants. These details enable shareholders to assess insider alignment and timing controls. No amendments or atypical transactions are reported beyond routine option holdings and plan-based sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roper Martin

(Last) (First) (Middle)

250 PARK AVE SOUTH

SEVENTH FLOOR

(Street)

NEW YORK NY 10003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vita Coco Company, Inc. [ COCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2025		S(1)		5,000	D	$40.006(2)	334,297	D
Common Stock	09/18/2025		S(1)		5,000	D	$40.009(3)	268,806	I	by Chris Roper FT(4)
Common Stock	09/18/2025		S(1)		5,000	D	$40.011(5)	267,915	I	by Peter Roper FT(6)
Common Stock	09/18/2025		S(1)		5,000	D	$40.007(7)	268,931	I	by Thomas Roper FT(8)
Common Stock								61,200	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$10.178							(9)	09/19/2029	Common Stock	579,670		579,670	D
Non-Qualified Stock Option (right to buy)	$10.178							(10)	01/11/2031	Common Stock	40,950		40,950	D
Non-Qualified Stock Option (right to buy)	$15							(11)	10/21/2031	Common Stock	298,507		298,507	D
Non-Qualified Stock Option (right to buy)	$16.91							(12)	03/10/2033	Common Stock	46,875		46,875	D
Non-Qualified Stock Option (right to buy)	$26.18							(13)	03/04/2034	Common Stock	62,743		62,743	D
Non-Qualified Stock Option (right to buy)	$32.78							(14)	03/03/2035	Common Stock	70,715		70,715	D

Explanation of Responses:

1. The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. These shares are held by the Christopher G. Roper Exempt Family Trust.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.11, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

6. These shares are held by the Peter S. Roper Exempt Family Trust.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.09, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

8. These shares are held by the Thomas L. Roper Exempt Family Trust.

9. The stock option is fully vested and currently exercisable.

10. The stock option is fully vested and currently exercisable.

11. The stock option vests in four equal annual installments beginning on November 27, 2022.

12. The stock option vests in four equal annual installments beginning on March 10, 2024.

13. The stock option vests in four equal annual installments beginning on March 4, 2025.

14. The Stock Option vests in four equal annual installments beginning in March 3, 2026.

	By: Alison Klein, Attorney-in-Fact For: Martin Roper	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Martin Roper report on the Form 4 for Vita Coco (COCO)?

The Form 4 reports that Martin Roper sold a total of 20,000 common shares on 09/18/2025 under a Rule 10b5-1 plan and discloses option holdings totaling 1,098,460 underlying shares.

Were the insider sales part of a prearranged plan for COCO?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan.

What were the prices for the shares sold by the insider?

The reported weighted average prices for the sold shares ranged from approximately $40.00 to $40.11 per share.

How many stock options does the filing disclose and what are the strike prices?

The filing discloses multiple non-qualified stock option grants aggregating to 1,098,460 underlying shares with exercise prices including $10.178, $15, $16.91, $26.18, and $32.78.

Are any of the options exercisable now?

Yes. The filing indicates certain options at a $10.178 exercise price are fully vested and currently exercisable.